Development of vaccines for Plasmodium vivax malaria.
Identifieur interne : 002B62 ( Ncbi/Merge ); précédent : 002B61; suivant : 002B63Development of vaccines for Plasmodium vivax malaria.
Auteurs : Ivo Mueller [Espagne] ; Ahmad Rushdi Shakri [Inde] ; Chetan E. Chitnis [France]Source :
- Vaccine [ 1873-2518 ] ; 2015.
Descripteurs français
- KwdFr :
- Afrique, Amérique du Sud, Humains, Iles du Pacifique, Paludisme à Plasmodium vivax (), Paludisme à Plasmodium vivax (immunologie), Paludisme à Plasmodium vivax (transmission), Plasmodium vivax (immunologie), Plasmodium vivax (physiologie), Recherche biomédicale, Vaccins contre le paludisme (immunologie), Étapes du cycle de vie (immunologie).
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical , immunology : Malaria Vaccines.
- geographic : Africa, Pacific Islands, South America.
- immunology : Life Cycle Stages, Malaria, Vivax, Plasmodium vivax.
- physiology : Plasmodium vivax.
- prevention & control : Malaria, Vivax.
- transmission : Malaria, Vivax.
- Biomedical Research, Humans.
Abstract
Plasmodium vivax continues to cause significant morbidity outside Africa with more than 50% of malaria cases in many parts of South and South-east Asia, Pacific islands, Central and South America being attributed to P. vivax infections. The unique biology of P. vivax, including its ability to form latent hypnozoites that emerge months to years later to cause blood stage infections, early appearance of gametocytes before clinical symptoms are apparent and a shorter development cycle in the vector makes elimination of P. vivax using standard control tools difficult. The availability of an effective vaccine that provides protection and prevents transmission would be a valuable tool in efforts to eliminate P. vivax. Here, we review the latest developments related to P. vivax malaria vaccines and discuss the challenges as well as directions toward the goal of developing highly efficacious vaccines against P. vivax malaria.
DOI: 10.1016/j.vaccine.2015.09.060
PubMed: 26428453
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002668
- to stream PubMed, to step Curation: 002599
- to stream PubMed, to step Checkpoint: 002599
Links to Exploration step
pubmed:26428453Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of vaccines for Plasmodium vivax malaria.</title><author><name sortKey="Mueller, Ivo" sort="Mueller, Ivo" uniqKey="Mueller I" first="Ivo" last="Mueller">Ivo Mueller</name><affiliation wicri:level="3"><nlm:affiliation>Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Institute of Global Health (ISGLOBAL), Barcelona, Spain. Electronic address: mueller@wehi.edu.au.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Institute of Global Health (ISGLOBAL), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Shakri, Ahmad Rushdi" sort="Shakri, Ahmad Rushdi" uniqKey="Shakri A" first="Ahmad Rushdi" last="Shakri">Ahmad Rushdi Shakri</name><affiliation wicri:level="1"><nlm:affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Chitnis, Chetan E" sort="Chitnis, Chetan E" uniqKey="Chitnis C" first="Chetan E" last="Chitnis">Chetan E. Chitnis</name><affiliation wicri:level="3"><nlm:affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India; Institut Pasteur, Paris, France. Electronic address: chetan.chitnis@pasteur.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India; Institut Pasteur, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26428453</idno><idno type="pmid">26428453</idno><idno type="doi">10.1016/j.vaccine.2015.09.060</idno><idno type="wicri:Area/PubMed/Corpus">002668</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002668</idno><idno type="wicri:Area/PubMed/Curation">002599</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002599</idno><idno type="wicri:Area/PubMed/Checkpoint">002599</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002599</idno><idno type="wicri:Area/Ncbi/Merge">002B62</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of vaccines for Plasmodium vivax malaria.</title><author><name sortKey="Mueller, Ivo" sort="Mueller, Ivo" uniqKey="Mueller I" first="Ivo" last="Mueller">Ivo Mueller</name><affiliation wicri:level="3"><nlm:affiliation>Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Institute of Global Health (ISGLOBAL), Barcelona, Spain. Electronic address: mueller@wehi.edu.au.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Institute of Global Health (ISGLOBAL), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Shakri, Ahmad Rushdi" sort="Shakri, Ahmad Rushdi" uniqKey="Shakri A" first="Ahmad Rushdi" last="Shakri">Ahmad Rushdi Shakri</name><affiliation wicri:level="1"><nlm:affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Chitnis, Chetan E" sort="Chitnis, Chetan E" uniqKey="Chitnis C" first="Chetan E" last="Chitnis">Chetan E. Chitnis</name><affiliation wicri:level="3"><nlm:affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India; Institut Pasteur, Paris, France. Electronic address: chetan.chitnis@pasteur.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India; Institut Pasteur, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Africa</term><term>Biomedical Research</term><term>Humans</term><term>Life Cycle Stages (immunology)</term><term>Malaria Vaccines (immunology)</term><term>Malaria, Vivax (immunology)</term><term>Malaria, Vivax (prevention & control)</term><term>Malaria, Vivax (transmission)</term><term>Pacific Islands</term><term>Plasmodium vivax (immunology)</term><term>Plasmodium vivax (physiology)</term><term>South America</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afrique</term><term>Amérique du Sud</term><term>Humains</term><term>Iles du Pacifique</term><term>Paludisme à Plasmodium vivax ()</term><term>Paludisme à Plasmodium vivax (immunologie)</term><term>Paludisme à Plasmodium vivax (transmission)</term><term>Plasmodium vivax (immunologie)</term><term>Plasmodium vivax (physiologie)</term><term>Recherche biomédicale</term><term>Vaccins contre le paludisme (immunologie)</term><term>Étapes du cycle de vie (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Malaria Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Africa</term><term>Pacific Islands</term><term>South America</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Paludisme à Plasmodium vivax</term><term>Plasmodium vivax</term><term>Vaccins contre le paludisme</term><term>Étapes du cycle de vie</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Life Cycle Stages</term><term>Malaria, Vivax</term><term>Plasmodium vivax</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Plasmodium vivax</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Plasmodium vivax</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Malaria, Vivax</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Malaria, Vivax</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Biomedical Research</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Afrique</term><term>Amérique du Sud</term><term>Humains</term><term>Iles du Pacifique</term><term>Paludisme à Plasmodium vivax</term><term>Recherche biomédicale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Plasmodium vivax continues to cause significant morbidity outside Africa with more than 50% of malaria cases in many parts of South and South-east Asia, Pacific islands, Central and South America being attributed to P. vivax infections. The unique biology of P. vivax, including its ability to form latent hypnozoites that emerge months to years later to cause blood stage infections, early appearance of gametocytes before clinical symptoms are apparent and a shorter development cycle in the vector makes elimination of P. vivax using standard control tools difficult. The availability of an effective vaccine that provides protection and prevents transmission would be a valuable tool in efforts to eliminate P. vivax. Here, we review the latest developments related to P. vivax malaria vaccines and discuss the challenges as well as directions toward the goal of developing highly efficacious vaccines against P. vivax malaria.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26428453</PMID><DateCreated><Year>2015</Year><Month>12</Month><Day>21</Day></DateCreated><DateCompleted><Year>2016</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>52</Issue><PubDate><Year>2015</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Development of vaccines for Plasmodium vivax malaria.</ArticleTitle><Pagination><MedlinePgn>7489-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2015.09.060</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(15)01336-5</ELocationID><Abstract><AbstractText>Plasmodium vivax continues to cause significant morbidity outside Africa with more than 50% of malaria cases in many parts of South and South-east Asia, Pacific islands, Central and South America being attributed to P. vivax infections. The unique biology of P. vivax, including its ability to form latent hypnozoites that emerge months to years later to cause blood stage infections, early appearance of gametocytes before clinical symptoms are apparent and a shorter development cycle in the vector makes elimination of P. vivax using standard control tools difficult. The availability of an effective vaccine that provides protection and prevents transmission would be a valuable tool in efforts to eliminate P. vivax. Here, we review the latest developments related to P. vivax malaria vaccines and discuss the challenges as well as directions toward the goal of developing highly efficacious vaccines against P. vivax malaria.</AbstractText><CopyrightInformation>Copyright © 2015. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Ivo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Institute of Global Health (ISGLOBAL), Barcelona, Spain. Electronic address: mueller@wehi.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shakri</LastName><ForeName>Ahmad Rushdi</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chitnis</LastName><ForeName>Chetan E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India; Institut Pasteur, Paris, France. Electronic address: chetan.chitnis@pasteur.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017780">Malaria Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000349" MajorTopicYN="N" Type="Geographic">Africa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008018" MajorTopicYN="N">Life Cycle Stages</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017780" MajorTopicYN="N">Malaria Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016780" MajorTopicYN="N">Malaria, Vivax</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010139" MajorTopicYN="N" Type="Geographic">Pacific Islands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010966" MajorTopicYN="N">Plasmodium vivax</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013020" MajorTopicYN="N" Type="Geographic">South America</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Blood stage malaria vaccines</Keyword><Keyword MajorTopicYN="N">Immunity to malaria</Keyword><Keyword MajorTopicYN="N">Malaria vaccines</Keyword><Keyword MajorTopicYN="N">P. vivax malaria</Keyword><Keyword MajorTopicYN="N">Parasitic diseases</Keyword><Keyword MajorTopicYN="N">Pre-erythrocytic stage malaria vaccines</Keyword><Keyword MajorTopicYN="N">Transmission blocking malaria vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>03</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>09</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26428453</ArticleId><ArticleId IdType="pii">S0264-410X(15)01336-5</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2015.09.060</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li><li>France</li><li>Inde</li></country><region><li>Catalogne</li><li>Île-de-France</li></region><settlement><li>Barcelone</li><li>Paris</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Mueller, Ivo" sort="Mueller, Ivo" uniqKey="Mueller I" first="Ivo" last="Mueller">Ivo Mueller</name></region></country><country name="Inde"><noRegion><name sortKey="Shakri, Ahmad Rushdi" sort="Shakri, Ahmad Rushdi" uniqKey="Shakri A" first="Ahmad Rushdi" last="Shakri">Ahmad Rushdi Shakri</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Chitnis, Chetan E" sort="Chitnis, Chetan E" uniqKey="Chitnis C" first="Chetan E" last="Chitnis">Chetan E. Chitnis</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B62 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002B62 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:26428453
|texte= Development of vaccines for Plasmodium vivax malaria.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:26428453" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |